Prenetics Global (PRE) Q3 2025 earnings summary

Executive summary

• Achieved a record quarter with flagship health and longevity brand (IMA/IM8) driving rapid transformation and global expansion.

• IMA/IM8 reached $100 million ARR in 11 months, with projections of $120 million ARR within 12 months of launch.

• Completed a $44 million strategic funding round, attracting high-profile investors and enhancing liquidity.

• Divested ACT Genomics, increasing focus on IMA/IM8 and streamlining the business.

• Record Q3 2025 results with revenue up 568% year-over-year to $23.6 million, driven by IMA/IM8's rapid growth.

Financial highlights

• Q3 2025 revenue surged 568% year-over-year to $23.6 million, with gross profit up 631.2% to $14.0 million.

• October revenue hit $9 million, with December expected to exceed $10 million.

• Adjusted EBITDA loss improved to $(2.1) million in Q3 2025, showing a clear path to profitability.

• Gross margin increased to 60% from 52% quarter-over-quarter.

• Maintains approximately $120 million in liquidity, zero debt, and $41 million in Bitcoin holdings.

Outlook and guidance

• Projecting IMA/IM8 to reach $120 million ARR by December 2025 and $300 million ARR by end of 2026.

• Full year 2025 revenue guidance reaffirmed at $90–$100 million, with IMA/IM8 contributing about $60 million.

• 2026 IMA/IM8 revenue expected between $180–$200 million, driven by international expansion and new products.

• Q4 2025 IM8 revenue guidance: $28 million, a 63% increase quarter-over-quarter.